<DOC>
	<DOC>NCT01357031</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of melatonin 3 mg compared to placebo and amitriptyline 25 mg in the preventive treatment of migraine.</brief_summary>
	<brief_title>Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine</brief_title>
	<detailed_description>The investigators propose a study of patients with migraine (episodic) with or without aura, according to the criteria of the International Headache Society (IHS) 2004. This will be a randomized clinical trial, prospective, double-blind, placebo-controlled, comparing the efficacy of melatonin 3 mg and amitriptyline 25 mg for migraine prevention. The length of the inclusion of the study will be 24 months. This study's general objective is: to evaluate the effectiveness of melatonin in the preventive treatment of migraine and compare it to placebo and amitriptyline.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Man or woman 18 to 65 years of age. Meets diagnostic criteria criteria of International Headache Society (IHS) 2004 (2) for migraine with and / or without aura. Frequency from 2 to 8 migraine attacks per month Top of crisis over a year and age of onset less than 50 years of age. Patients want to participate in the study, and able to give informed consent. If women, the patient must be willing to use an acceptable method of birth control (eg, a hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide, or refer abstinence). Patient able and willing to remain on their medications throughout the study. Accept the guidelines of the study by filling out the diary and clinical scales. Any medical condition that places the patient at risk with its exposure to melatonin or amitryptiline Use of alcohol and drugs. Be receiving prophylactic medication in the last three months. History of hemiplegic migraine, basilar, Ophthalmoplegic or stroke. Headache secondary to head trauma or a whiplash neck injury (whiplash). Pregnant or breastfeeding. Women planning to become pregnant or of childbearing age without acceptable method of contraception. Women who began taking oral contraceptives or who switched their oral contraceptive regimen in the 6 months prior to the start of the study. Allergy or known hypersensitivity to study medication or its components. Participation in another clinical study one month before inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Amitriptyline</keyword>
	<keyword>Placebo</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Preventive treatment of migraine</keyword>
</DOC>